SC75741

Description: SC75741 (SC-75741; SC 75741) is a novel, selective and potent NF-kappaB inhibitor with potential antiviral and anti-inflammatory activity. It inhibits NF-kappaB with an EC50 of 200 nM. SC75741 blocks influenza viruses (IV) replication in non-toxic concentrations. SC75741 impairs DNA binding of the NF-kappaBsubunit p65, resulting in reduced expression of cytokines, chemokines, and pro-apoptotic factors. SC75741 subsequently inhibits caspaseactivation and blocks caspase-mediated nuclear export of viralribonucleoproteins. In MDCK cells, inhibitory potential of 5 uM SC75741 on virus replication is highest at later stages of infection. In the human alveolar type II epithelial cell line A549 infected with H5N1 and H7N7 viruses, SC75741 provoked an efficient reduction of virus titers in a dose-dependent way. In the lung of infected mice, SC75741 reduces viral replication and H5N1-induced IL6 and IP-10 expression. In addition, SC75741 also reduced cytokine production in vivo that is involved in hypercytokinemia mediated by influenza virus infection. Importantly, SC75741 exhibits a high barrier for virus variants.

References: Bioorg Med Chem Lett. 2007 Nov 1; 17(21):5858-62; Cell Microbiol. 2013 Jul; 15(7):1198-211.

SC-75741; SC 75741; SC75741;